These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25363547)

  • 1. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.
    Singh S
    Curr Diab Rep; 2014 Dec; 14(12):563. PubMed ID: 25363547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on therapies to metformin for type 2 diabetes.
    Shomali M
    Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral hypoglycemic agents on platelet function.
    Papazafiropoulou A; Papanas N; Pappas S; Maltezos E; Mikhailidis DP
    J Diabetes Complications; 2015 Aug; 29(6):846-51. PubMed ID: 26026848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
    Rustenbeck I
    Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
    Taylor JR; Dietrich E; Powell JG
    Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
    Avogaro A
    G Ital Cardiol (Rome); 2016 Apr; 17(4):248-52. PubMed ID: 27093207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
    Tuccori M; Convertino I; Galiulo MT; Marino A; Capogrosso-Sansone A; Blandizzi C
    Expert Opin Drug Saf; 2017 Oct; 16(10):1133-1148. PubMed ID: 28748718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.
    Derosa G; Maffioli P
    Diabetes Technol Ther; 2010 Jun; 12(6):491-501. PubMed ID: 20470234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.